沃森生物
(300142)
| 流通市值：173.72亿 | | | 总市值：176.09亿 |
| 流通股本：15.78亿 | | | 总股本：15.99亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,146,917,150.37 | 834,215,184.81 | 443,848,309.81 | 2,418,234,933.46 |
| 营业收入 | 1,146,917,150.37 | 834,215,184.81 | 443,848,309.81 | 2,418,234,933.46 |
| 二、营业总成本 | 1,156,791,774 | 803,971,819.98 | 406,874,077.19 | 2,107,110,191.82 |
| 营业成本 | 381,983,001.55 | 260,366,621.65 | 139,961,391.93 | 615,248,686.86 |
| 税金及附加 | 17,530,080.42 | 11,108,274.79 | 4,826,597.58 | 20,220,884.37 |
| 销售费用 | 369,743,864.74 | 275,726,149.7 | 154,161,138.34 | 854,091,902.74 |
| 管理费用 | 208,347,522.86 | 136,056,476.69 | 60,530,231.72 | 392,125,961.18 |
| 研发费用 | 156,549,925.53 | 107,990,027.97 | 43,803,178.56 | 291,877,572.4 |
| 财务费用 | 22,637,378.9 | 12,724,269.18 | 3,591,539.06 | -66,454,815.73 |
| 其中:利息费用 | 27,159,806.4 | 16,664,593.85 | 7,056,519.82 | -2,217,643.94 |
| 其中:利息收入 | 15,843,981.65 | 11,016,310.03 | 6,125,280 | 67,238,667.68 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -60,953,400 | -58,734,900 | -19,057,700 | 29,676,000 |
| 加:投资收益 | 3,678,922.23 | -74,954.33 | -238,170.48 | 2,537,266.79 |
| 资产处置收益 | 350,961.45 | 351,321.33 | -12,864.06 | 81,071.48 |
| 资产减值损失(新) | -15,347,995.9 | -7,883,113.69 | -13,345,508.8 | -102,730,882.64 |
| 信用减值损失(新) | 66,995,053.6 | 76,102,055.82 | 102,668,329.38 | -148,933,720.99 |
| 其他收益 | 44,983,540.23 | 33,426,270.14 | 24,066,538.7 | 96,194,833.83 |
| 四、营业利润 | 29,832,457.98 | 73,430,044.1 | 131,054,857.36 | 187,949,310.11 |
| 加:营业外收入 | 149,936.76 | 148,799.38 | 15,209.44 | 731,624.75 |
| 减:营业外支出 | 6,249,029.54 | 4,372,642.32 | 2,131,941.21 | 22,568,541.63 |
| 五、利润总额 | 23,733,365.2 | 69,206,201.16 | 128,938,125.59 | 166,112,393.23 |
| 减:所得税费用 | 26,965,016.89 | 23,267,027.6 | 14,524,255.9 | 40,955,301.8 |
| 六、净利润 | -3,231,651.69 | 45,939,173.56 | 114,413,869.69 | 125,157,091.43 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -3,231,651.69 | 45,939,173.56 | 114,413,869.69 | 125,157,091.43 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 7,536,960.37 | 54,192,194.54 | 110,677,005.66 | 177,741,534.7 |
| 少数股东损益 | -10,768,612.06 | -8,253,020.98 | 3,736,864.03 | -52,584,443.27 |
| 扣除非经常损益后的净利润 | 46,737,314.76 | 94,944,847.48 | 113,661,365.91 | 95,450,860.28 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0 | 0.03 | 0.07 | 0.11 |
| (二)稀释每股收益 | 0 | 0.03 | 0.07 | 0.11 |
| 八、其他综合收益 | - | 32,392.13 | - | 213,017,400 |
| 归属于母公司股东的其他综合收益 | - | 32,392.13 | - | 213,017,400 |
| 九、综合收益总额 | -3,231,651.69 | 45,971,565.69 | 114,413,869.69 | 338,174,491.43 |
| 归属于母公司股东的综合收益总额 | 7,536,960.37 | 54,224,586.67 | 110,677,005.66 | 390,758,934.7 |
| 归属于少数股东的综合收益总额 | -10,768,612.06 | -8,253,020.98 | 3,736,864.03 | -52,584,443.27 |
| 公告日期 | 2026-10-30 | 2026-08-29 | 2026-04-28 | 2026-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |